Cinacalcet Tablet Franchise in Ahmedabad

Cinacalcet Tablet Franchise in Ahmedabad

Hyperparathyroidism Tablet Distributor in Delhi

Hyperparathyroidism Tablet Distributor in Delhi

Cinacalcet Tablet Manufacturer in Bangalore
Cinacalcet Tablet Exporter in Chandigarh

Home/Products /cinacalcet-90mg-tablet

Cinaclat 90 Tablet

Composition : Cinacalcet (90mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹0/-

Cinaclat 90 Tablet contains Cinacalcet 90 mg, a strong calcimimetic agent indicated for secondary hyperparathyroidism in chronic kidney disease (CKD) patients on dialysis and parathyroid carcinoma. By enhancing calcium-sensing receptor sensitivity on parathyroid glands, it reduces PTH secretion and controls serum calcium levels effectively.

This high-dose formulation is ideal for patients with persistent elevated PTH or hypercalcemia, requiring potent therapy for long-term metabolic control. Cinacalcet helps prevent bone complications, vascular calcifications, and other metabolic disturbances associated with CKD.

Clinically, Cinaclat 90 Tablet is indicated for secondary hyperparathyroidism, parathyroid carcinoma, and related calcium-phosphate metabolic disorders, providing consistent therapeutic outcomes and improved patient management.

The tablet offers precise dosing, convenient oral administration, and reliable clinical effect, making it suitable for hospital, dialysis, and long-term outpatient care.

Read More

About the Product

Cinaclat 90 Tablet contains Cinacalcet 90 mg, a strong calcimimetic agent indicated for secondary hyperparathyroidism in chronic kidney disease (CKD) patients on dialysis and parathyroid carcinoma. By enhancing calcium-sensing receptor sensitivity on parathyroid glands, it reduces PTH secretion and controls serum calcium levels effectively.

This high-dose formulation is ideal for patients with persistent elevated PTH or hypercalcemia, requiring potent therapy for long-term metabolic control. Cinacalcet helps prevent bone complications, vascular calcifications, and other metabolic disturbances associated with CKD.

Clinically, Cinaclat 90 Tablet is indicated for secondary hyperparathyroidism, parathyroid carcinoma, and related calcium-phosphate metabolic disorders, providing consistent therapeutic outcomes and improved patient management.

The tablet offers precise dosing, convenient oral administration, and reliable clinical effect, making it suitable for hospital, dialysis, and long-term outpatient care.

Common side effects may include nausea, vomiting, hypocalcemia, headache, and dizziness. Rarely, severe hypocalcemia, muscle cramps, or allergic reactions may occur.

Cinaclat 90 Tablet is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and for management of hypercalcemia in patients with parathyroid carcinoma. It helps in controlling mineral metabolism and maintaining bone and cardiovascular health.

Use Cinaclat 90 Tablet strictly under medical supervision. Regular monitoring of serum calcium, phosphate, and PTH levels is essential. Inform your doctor if you have a history of hypocalcemia, heart rhythm disorders, or gastrointestinal issues. Seek immediate medical attention if severe muscle cramps, numbness, or irregular heartbeat develops.

Store in a cool, dry place below 25°C. Protect from moisture and direct sunlight. Keep out of reach of children. Do not use beyond the expiry date.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation